Chemistry:Saruparib
From HandWiki
Saruparib is an investigational new drug that is being evaluated for the treatment of cancer.[1] It first-in-class selective inhibitor of poly-ADP ribose polymerase 1 (PARP1), designed to treat cancers with homologous recombination repair (HRR) deficiencies as a result of mutations in BRCA1, BRCA2, PALB2, RAD51C, or RAD51D genes.[2]
References
- ↑ "Saruparib - AstraZeneca". AdisInsight. Springer Nature Switzerland AG. https://adisinsight.springer.com/drugs/800061330.
- ↑ "The PARP1 selective inhibitor saruparib (AZD5305) elicits potent and durable antitumor activity in patient-derived BRCA1/2-associated cancer models". Genome Medicine 16 (1): 107. August 2024. doi:10.1186/s13073-024-01370-z. PMID 39187844.
 |  |
